Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals

Karl Claxton

Health Economics, 1999, vol. 8, issue 3, 269-274

Abstract: The current regulation of new pharmaceuticals is inefficient because it demands arbitrary amounts of information, the type of information demanded is not relevant to decision‐makers and the same standards of evidence are applied across different technologies. Bayesian decision theory and an analysis of the value of both perfect and sample information is used to consider the efficient regulation of new pharmaceuticals. This type of analysis can be used to decide whether the evidence in an economic study provides ‘sufficient substantiation’ for an economic claim, and assesses whether evidence can be regarded as ‘competent and reliable’. Copyright © 1999 John Wiley & Sons, Ltd.

Date: 1999
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (35)

Downloads: (external link)
https://doi.org/10.1002/(SICI)1099-1050(199905)8:33.0.CO;2-D

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:8:y:1999:i:3:p:269-274

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().